Sage Therapeutics (NASDAQ:SAGE) Given “Neutral” Rating at Piper Sandler
Piper Sandler restated their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $8.50 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $9.00. A number of other brokerages also recently commented on SAGE. […]
Piper Sandler restated their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $8.50 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $9.00. A number of other brokerages also recently commented on SAGE. […]
